ConMed Corp. (NYSE: CNMD), a surgical-device maker originally based in the Mohawk Valley region, recently announced that Kim Kelderman joined its board of directors, effective Sept. 8. “My fellow directors and I are delighted to welcome Kim to the board,” LaVerne Council, chair of ConMed’s board, said in the announcement. “Kim brings extensive global leadership […]
Already an Subcriber? Log in
Get Instant Access to This Article
Become a Central New York Business Journal subscriber and get immediate access to all of our subscriber-only content and much more.
- Critical Central New York business news and analysis updated daily.
- Immediate access to all subscriber-only content on our website.
- Get a year's worth of the Print Edition of The Central New York Business Journal.
- Special Feature Publications such as the Book of Lists and Revitalize Greater Binghamton, Mohawk Valley, and Syracuse Magazines
Click here to purchase a paywall bypass link for this article.
ConMed Corp. (NYSE: CNMD), a surgical-device maker originally based in the Mohawk Valley region, recently announced that Kim Kelderman joined its board of directors, effective Sept. 8.
“My fellow directors and I are delighted to welcome Kim to the board,” LaVerne Council, chair of ConMed’s board, said in the announcement. “Kim brings extensive global leadership experience across life sciences businesses, with a strong track record in innovation and strategy. Kim’s skills and insights will be valuable additions to the board.”
Kelderman has been president, CEO, and member of the board of Bio-Techne Corporation (NASDAQ: TECH) — a global provider of life-science tools, reagents and diagnostic products based in Minneapolis — since February 2024. He first joined Bio-Techne in April 2018, as president, diagnostics, and genomics, and served as chief operating officer from November 2023 to January 2024. Bio-Techne generated more than $1.2 billion in net sales in fiscal-year 2025 and has about 3,100 employees worldwide.
Prior to Bio-Techne, Kelderman worked at Thermo Fisher Scientific, where he led three different businesses of increasing scale and complexity. Kelderman managed the platforms and content of the Genetic Sciences Division, where he was responsible for the Instrumentation, Software, Consumables and Assays businesses, and brands such as Applied Biosystems and legacy Affymetrix. Before joining Thermo Fisher, Kelderman served as senior segment leader at Becton Dickinson, managing the global Blood Tubes “Vacutainer” business. Kelderman holds a bachelor’s degree from Hogeschool Heerlen of Applied Sciences in the Netherlands.
“Kim is an excellent addition to the board,” said Patrick Beyer, president and CEO of ConMed. “We are excited to benefit from his extensive experience and valuable perspective as we pursue our long-term vision and deliver value across our stakeholder community.”
ConMed is a medical technology company that provides devices and equipment for surgical procedures. Surgeons and other health-care professionals use the firm’s products in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. ConMed reported net sales of $663.6 million in the first six months of 2025, up 3 percent from nearly $644.4 million in the first half of 2024.
Based in Largo, Florida (Tampa Bay area) since 2021, ConMed still operates a facility on French Road in New Hartford, where it was formerly headquartered. The company employs about 3,500 people worldwide.


